The biotech sector is experiencing a powerful innovation cycle, with the iShares Biotechnology ETF (IBB) gaining 24% through October 23, building on a 28% gain in 2025 [1]. Moderna leads the sector with a remarkable 587% surge year-to-date, despite an 18% single-day decline following a leak of clinical data for its cancer vaccine [1]. Two dozen of the ETF's 233 holdings have more than doubled year-to-date, signaling broad-based strength across the sector [1].
The rally is being driven by multiple catalysts, including clinical trial results, mergers and acquisition activity, and emerging technologies such as genomics, mRNA, and artificial intelligence [1]. John Hall, portfolio manager of the T. Rowe Price Biotechnology ETF, noted that "we're in the midst of a powerful innovation cycle" with "newer modalities start to make it to market" [1]. The FDA approved approximately a dozen novel biologic drugs in 2025 out of 46 total approvals, with roughly 66 novel drugs in the pipeline for FDA approval, including potential blockbusters like Moderna and Merck's cancer drug for melanoma and a next-generation obesity drug from Eli Lilly [1].
Artificial intelligence is emerging as a significant catalyst for accelerating drug development. According to Piper Sandler analyst Ted Tenthoff, "Biotech is a phenomenal application for artificial intelligence and machine learning" with the potential to create "predictive models that, frankly, can do things that we've never been able to do in the space in terms of novel drug discovery" [1]. The global AI in drug discovery market is forecasted to expand dramatically from $20 billion in 2025 to more than $160 billion by 2035, according to research firm Towards Health [1].
Moderna and Merck's melanoma drug exemplifies the innovation driving investor enthusiasm. The mRNA-based therapeutic showed a 42% reduction in cancer recurrence or death when used in conjunction with Merck's Keytruda in Phase 3 trials [1]. While Wall Street initially disappointed by the results, oncologists view the outcomes as highly positive and see the technology as potentially transformative for personalized cancer treatments [1]. Moderna and Merck have indicated plans to submit the drug for FDA approval and launch it [1].
CONCLUSION
The biotech sector is experiencing a robust bull market driven by clinical innovation, AI-accelerated drug discovery, and a strong pipeline of novel therapeutics. With the IBB ETF up 24% year-to-date and numerous holdings doubling in value, investors are positioning for continued gains as AI deployment and mRNA technologies reshape drug development timelines and efficacy outcomes.